Dana Investment Advisors Inc. cut its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 7.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,409 shares of the biotechnology company’s stock after selling 1,315 shares during the period. […]
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a report released on Wednesday, Benzinga reports. They presently have a $65.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 122.76% from the stock’s current price. Several […]
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued ratings on the […]
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has been assigned a consensus rating of “Buy” from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have issued a report on […]
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW – Free Report) saw a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 100 shares, a decline of 50.0% from the May 31st total of 200 shares. Based on an average daily volume of 2,500 shares, the days-to-cover ratio is […]